premature stop codon mutations

PTC Therapeutics says it plans to conduct additional trials of ataluren

posted on July 31, 2012 - 12:37pm
New Jersey biopharmaceutical company PTC Therapeutics recently declared its intention to do whatever it takes — including an additional clinical trial — to seek approval for ataluren (formerly PTC124) as a treatment for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) caused by non

New content is being added every day. Please check back again.